From our Research, The Biologics Paradigm: Wharton's Jelly Mesenchymal Exosomes as a Section 351(a) Drug vs. The Section 361 Regulatory Grey Market

In our opinion, the landscape of regenerative medicine is undergoing a profound shift from whole-cell therapies to cell-free biologicals. Mesenchymal stem/stromal cell-derived extracellular vesicles—specifically exosomes derived from Wharton's Jelly (WJ-MSCs)—demonstrate immense potential for modulating inflammation and driving tissue regeneration across multiple body systems. However, the commercial trajectory of exosomes has been severely compromised by bad actors operating within an unregulated "grey market." Many clinics unlawfully market uncharacterized exosome cosmetics and tissue solutions under the guise of Section 361 of the Public Health Service (PHS) Act.

This white paper aggressively dissects the regulatory and biological realities of WJ-MSC exosomes. It establishes unequivocally that exosomes are more than minimally manipulated, function systemically, and therefore must traverse the rigorous Investigational New Drug (IND) and Biologics License Application (BLA) pathway under Section 351(a). Furthermore, by navigating legitimate federal and state legislative frameworks—including Regenerative Medicine Advanced Therapy (RMAT) designation, federal Right-to-Try laws, progressive state-level statutes (such as the updated 2025 Texas Medical Board standards and Florida's medical practice updates), and understanding cross-border regulatory arbitrage—compliantly manufactured exosomes can be made legally accessible to patients in need today. By establishing Current Good Manufacturing Practice (cGMP) standards and pursuing lawful clinical evaluation, WJ-MSC exosomes represent the gold standard for safe, compliant, and transformative regenerative medicine.